Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety

U. A. Matulonis, R. T. Penson, S. M. Domchek, B. Kaufman, R. Shapira-Frommer, M. W. Audeh, S. Kaye, L. R. Molife, K. A. Gelmon, J. D. Robertson, H. Mann, T. W. Ho, R. L. Coleman

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.

Original languageEnglish
Pages (from-to)1013-1019
Number of pages7
JournalAnnals of Oncology
Volume27
Issue number6
DOIs
StatePublished - 18 Jun 2016
Externally publishedYes

Keywords

  • BRCA1/2 mutation
  • monotherapy
  • olaparib
  • ovarian cancer
  • pooled analysis

Fingerprint

Dive into the research topics of 'Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety'. Together they form a unique fingerprint.

Cite this